Related Experiment Video
Updated: Dec 31, 2025

A Simple Pit Assay Protocol to Visualize and Quantify Osteoclastic Resorption In Vitro
Published on: June 16, 2022
Rev-erbα Negatively Regulates Osteoclast and Osteoblast Differentiation through p38 MAPK Signaling Pathway
Kabsun Kim1, Jung Ha Kim1, Inyoung Kim1
1Department of Pharmacology, Chonnam National University Medical School, Gwangju 61469, Korea.
Abstract:
The circadian clock regulates various physiological processes, including bone metabolism. The nuclear receptors Reverbs, comprising Rev-erbα and Rev-erbβ, play a key role as transcriptional regulators of the circadian clock. In this study, we demonstrate that Rev-erbs negatively regulate differentiation of osteoclasts and osteoblasts. The knockdown of Rev-erbα in osteoclast precursor cells enhanced receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclast formation, as well as expression of nuclear factor of activated T cells 1 (NFATc1), osteoclast-associated receptor (OSCAR), and tartrate-resistant acid phosphatase (TRAP). The overexpression of Rev-erbα leads to attenuation of the NFATc1 expression via inhibition of recruitment of c-Fos to the NFATc1 promoter. The overexpression of Rev-erbα in osteoblast precursors attenuated the expression of osteoblast marker genes including Runx2, alkaline phosphatase (ALP), bone sialoprotein (BSP), and osteocalcin (OC). Rev-erbα interfered with the recruitment of Runx2 to the promoter region of the target genes. Conversely, knockdown of Reverbα in the osteoblast precursors enhanced the osteoblast differentiation and function. In addition, Rev-erbα negatively regulated osteoclast and osteoblast differentiation by suppressing the p38 MAPK pathway. Furthermore, intraperitoneal administration of GSK4112, a Rev-erb agonist, protects RANKL-induced bone loss via inhibition of osteoclast differentiation in vivo . Taken together, our results demonstrate a molecular mechanism of Rev-erbs in the bone remodeling, and provide a molecular basis for a potential therapeutic target for treatment of bone disease characterized by excessive bone resorption.
Insights
Rev-erbs, key circadian clock regulators, negatively control bone cell differentiation. Targeting Rev-erbs offers a new therapeutic strategy for bone diseases like osteoporosis by modulating bone remodeling.
Area of Science:
- Molecular Biology
- Endocrinology
- Chronobiology
Background:
- The circadian clock influences bone metabolism.
- Nuclear receptors Rev-erbα and Rev-erbβ are crucial circadian regulators.
Purpose of the Study:
- To investigate the role of Rev-erbs in osteoclast and osteoblast differentiation.
- To elucidate the molecular mechanisms underlying Rev-erb action in bone remodeling.
Main Methods:
- Knockdown and overexpression of Rev-erbα in osteoclast and osteoblast precursor cells.
- Analysis of gene expression (NFATc1, OSCAR, TRAP, Runx2, ALP, BSP, OC).
- In vivo studies using a Rev-erb agonist (GSK4112) to assess bone loss.
Main Results:
- Rev-erbα knockdown enhanced osteoclast formation and osteoblast differentiation.
- Rev-erbα suppressed osteoblast marker gene expression by interfering with Runx2 recruitment.
- Rev-erbα negatively regulated bone cell differentiation via the p38 MAPK pathway.
- GSK4112 administration protected against bone loss in vivo.
Conclusions:
- Rev-erbs act as negative regulators of both osteoclast and osteoblast differentiation.
- Rev-erbα influences bone remodeling by modulating key transcription factors and signaling pathways.
- Rev-erb agonists represent a potential therapeutic target for bone diseases characterized by excessive resorption.
Related Concept Videos
Osteoclasts in Bone Remodeling
Negative Regulator Molecules
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
TGF - β Signaling Pathway
Bone Remodeling
MAPK Signaling Cascades

